{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:42:24Z","timestamp":1775151744775,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":2754,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.virol.2005.09.004","type":"journal-article","created":{"date-parts":[[2005,10,15]],"date-time":"2005-10-15T07:10:54Z","timestamp":1129360254000},"page":"363-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Enhanced humoral HIV-1-specifc immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2"],"prefix":"10.1016","volume":"344","author":[{"given":"James P.","family":"McGettigan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin L.","family":"Koser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ellen","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Marvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence C.","family":"Eisenlohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Dietzschold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.virol.2005.09.004_bib1","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.4049\/jimmunol.148.12.3820","article-title":"IL-4 plays a dominant role in the differential development of Tho into Th1 and Th2 cells","volume":"148","author":"Abehsira-Amar","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2005.09.004_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.292.5514.69","article-title":"Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine","volume":"292","author":"Amara","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.virol.2005.09.004_bib3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1073\/pnas.73.2.442","article-title":"Order of transcription of genes of vesicular stomatitis virus","volume":"73","author":"Ball","year":"1976","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.virol.2005.09.004_bib4","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1128\/JVI.73.6.4705-4712.1999","article-title":"Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus","volume":"73","author":"Ball","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2005.09.004_bib5","first-page":"85","article-title":"Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys","volume":"104","author":"Barouch","year":"2000","journal-title":"Dev. Biol."},{"key":"10.1016\/j.virol.2005.09.004_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1126\/science.290.5491.486","article-title":"Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination","volume":"290","author":"Barouch","year":"2000","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.virol.2005.09.004_bib7","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1128\/JVI.73.9.7430-7440.1999","article-title":"Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251","volume":"73","author":"Buge","year":"1999","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.virol.2005.09.004_bib8","first-page":"3403","article-title":"Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques","volume":"5","author":"Chakrabarti","year":"1985","journal-title":"Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.virol.2005.09.004_bib9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.4049\/jimmunol.160.3.1320","article-title":"Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes","volume":"160","author":"Chow","year":"1998","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.virol.2005.09.004_bib10","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/515288","article-title":"Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group","volume":"177","author":"Clements-Mann","year":"1998","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.virol.2005.09.004_bib11","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1073\/pnas.0400339101","article-title":"Interleukin 2 plays a central role in Th2 differentiation","volume":"101","author":"Cote-Sierra","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"10.1016\/j.virol.2005.09.004_bib12","doi-asserted-by":"crossref","first-page":"10199","DOI":"10.1128\/JVI.73.12.10199-10207.1999","article-title":"Characterization of primary isolate-like variants of simian\u2013human immunodeficiency virus","volume":"73","author":"Crawford","year":"1999","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2005.09.004_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0966-842X(93)90035-P","article-title":"Antibody-mediated clearance of viruses from the mammalian central nervous system","volume":"1","author":"Dietzschold","year":"1993","journal-title":"Trends Microbiol."},{"issue":"1","key":"10.1016\/j.virol.2005.09.004_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0042-6822(87)90167-X","article-title":"Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies","volume":"161","author":"Dietzschold","year":"1987","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.virol.2005.09.004_bib15","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1128\/jvi.64.8.3804-3809.1990","article-title":"Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine","volume":"64","author":"Dietzschold","year":"1990","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virol.2005.09.004_bib16","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1128\/jvi.68.5.3015-3026.1994","article-title":"Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities","volume":"68","author":"Earl","year":"1994","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.virol.2005.09.004_bib17","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1128\/JVI.72.10.8437-8445.1998","article-title":"Characterization of simian\u2013human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys","volume":"72","author":"Etemad-Moghadam","year":"1998","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.virol.2005.09.004_bib18","doi-asserted-by":"crossref","first-page":"8672","DOI":"10.1128\/jvi.71.11.8672-8677.1997","article-title":"Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus","volume":"71","author":"Fischer","year":"1997","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.virol.2005.09.004_bib19","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1128\/JVI.74.17.7895-7902.2000","article-title":"Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response","volume":"74","author":"Flanagan","year":"2000","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.virol.2005.09.004_bib20","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1128\/JVI.75.13.6107-6114.2001","article-title":"Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development","volume":"75","author":"Flanagan","year":"2001","journal-title":"J. Virol."},{"issue":"97","key":"10.1016\/j.virol.2005.09.004_bib21","doi-asserted-by":"crossref","first-page":"14680","DOI":"10.1073\/pnas.011510698","article-title":"A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection","author":"Foley","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.virol.2005.09.004_bib22","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.4049\/jimmunol.162.11.6724","article-title":"IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner","volume":"162","author":"Gherardi","year":"1999","journal-title":"J. Immunol."},{"issue":"14","key":"10.1016\/j.virol.2005.09.004_bib23","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1128\/JVI.74.14.6278-6286.2000","volume":"74","author":"Gherardi","year":"2000","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.virol.2005.09.004_bib24","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1128\/JVI.77.12.7048-7057.2003","article-title":"Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes","volume":"77","author":"Gherardi","year":"2003","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.virol.2005.09.004_bib25","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.4049\/jimmunol.172.10.6209","article-title":"Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule","volume":"172","author":"Gherardi","year":"2004","journal-title":"J. Immunol."},{"issue":"19","key":"10.1016\/j.virol.2005.09.004_bib26","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1128\/JVI.75.19.9029-9036.2001","article-title":"Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice","volume":"75","author":"Ghiasi","year":"2001","journal-title":"J. Virol."},{"issue":"7\u20138","key":"10.1016\/j.virol.2005.09.004_bib27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0264-410X(98)00274-6","article-title":"Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants","volume":"17","author":"Gonzalo","year":"1999","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.virol.2005.09.004_bib28","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1128\/JVI.76.15.7506-7517.2002","article-title":"Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins","volume":"76","author":"Haglund","year":"2002","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.virol.2005.09.004_bib29","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1073\/pnas.89.13.6065","article-title":"Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system","volume":"89","author":"Hsieh","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.virol.2005.09.004_bib30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JVI.75.3.1205-1210.2001","article-title":"Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox","volume":"75","author":"Jackson","year":"2001","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.virol.2005.09.004_bib31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1471-4906(01)01975-5","article-title":"Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways","volume":"22","author":"Jankovic","year":"2001","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.virol.2005.09.004_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/eji.1830160809","article-title":"The roles of interleukin 2 and interferon-gamma in human B cell activation, growth and differentiation","volume":"16","author":"Jelinek","year":"1986","journal-title":"Eur. J. Immunol."},{"issue":"Pt 9","key":"10.1016\/j.virol.2005.09.004_bib33","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1099\/0022-1317-82-9-2107","article-title":"Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine","volume":"82","author":"Johnson","year":"2001","journal-title":"J. Gen. Virol."},{"issue":"12","key":"10.1016\/j.virol.2005.09.004_bib34","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1128\/JVI.72.12.10180-10188.1998","article-title":"Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus","volume":"72","author":"Kent","year":"1998","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.virol.2005.09.004_bib35","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/S0264-410X(99)00559-9","article-title":"A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques","volume":"18","author":"Kent","year":"2000","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.virol.2005.09.004_bib36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L","article-title":"Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens","volume":"28","author":"Kim","year":"1998","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.virol.2005.09.004_bib37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/107999000312450","article-title":"Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo","volume":"20","author":"Kim","year":"2000","journal-title":"J. Interferon Cytokine Res."},{"issue":"3","key":"10.1016\/j.virol.2005.09.004_bib38","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2005.09.004_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2004.00203.x","article-title":"Cytokine and immunodeficiency diseases: critical roles of the gamma (c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways","volume":"202","author":"Kovanen","year":"2004","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.virol.2005.09.004_bib40","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/10799900050044787","article-title":"Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses","volume":"20","author":"Lee","year":"2000","journal-title":"J. Interferon Cytokine Res."},{"issue":"11","key":"10.1016\/j.virol.2005.09.004_bib41","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1073\/pnas.90.11.5214","article-title":"Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria","volume":"90","author":"Li","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.virol.2005.09.004_bib42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.virol.2005.09.004_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.75.9.4430-4434.2001","article-title":"Rabies virus-based vectors expressing HIV-1 envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates","volume":"75","author":"McGettigan","year":"2001","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.virol.2005.09.004_bib44","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/JVI.75.9.4430-4434.2001","article-title":"Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates","volume":"75","author":"McGettigan","year":"2001","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.virol.2005.09.004_bib45","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1128\/JVI.75.18.8724-8732.2001","article-title":"Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector","volume":"75","author":"McGettigan","year":"2001","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.virol.2005.09.004_bib46","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1128\/JVI.77.20.10889-10899.2003","article-title":"Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome","volume":"77","author":"McGettigan","year":"2003","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virol.2005.09.004_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.77.1.237-244.2003","article-title":"Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic","volume":"77","author":"McGettigan","year":"2003","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2005.09.004_bib48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1570162033485320","article-title":"Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases","volume":"1","author":"McKenna","year":"2003","journal-title":"Curr. HIV Res."},{"issue":"23","key":"10.1016\/j.virol.2005.09.004_bib49","doi-asserted-by":"crossref","first-page":"12782","DOI":"10.1128\/JVI.77.23.12782-12794.2003","article-title":"Covalently linked human immunodeficiency virus type 1 gp120\/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes","volume":"77","author":"McKenna","year":"2003","journal-title":"J. Virol."},{"issue":"1\u20133","key":"10.1016\/j.virol.2005.09.004_bib50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0169-409X(01)00169-7","article-title":"Manipulating the immune system: humoral versus cell-mediated immunity","volume":"51","author":"McNeela","year":"2001","journal-title":"Adv. Drug Delivery Rev."},{"issue":"4","key":"10.1016\/j.virol.2005.09.004_bib51","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1128\/JVI.72.4.3427-3431.1998","article-title":"Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1","volume":"72","author":"Montefiori","year":"1998","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.virol.2005.09.004_bib52","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/jvi.70.8.5230-5235.1996","article-title":"Interleukin-4 causes delayed virus clearance in influenza virus-infected mice","volume":"70","author":"Moran","year":"1996","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.virol.2005.09.004_bib53","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1128\/jvi.65.7.3429-3434.1991","article-title":"Role of CD4+ and CD8+ T cells in murine resistance to street rabies virus","volume":"65","author":"Perry","year":"1991","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.virol.2005.09.004_bib54","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1128\/JVI.74.13.5997-6005.2000","article-title":"Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway","volume":"74","author":"Qiu","year":"2000","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2005.09.004_bib55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/jvi.70.2.753-762.1996","article-title":"Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein","volume":"70","author":"Richardson","year":"1996","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virol.2005.09.004_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.virol.2005.09.004_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1574-6968.2001.tb10703.x","article-title":"Viral vectors as potential HIV-1 vaccines","volume":"200","author":"Schnell","year":"2001","journal-title":"FEMS Microbiol. Lett."},{"issue":"18","key":"10.1016\/j.virol.2005.09.004_bib58","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","article-title":"Infectious rabies viruses from cloned cDNA","volume":"13","author":"Schnell","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.virol.2005.09.004_bib59","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1073\/pnas.97.7.3544","article-title":"Recombinant rabies virus as potential live-viral vaccines for HIV-1","author":"Schnell","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.virol.2005.09.004_bib60","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1128\/jvi.70.10.7103-7107.1996","article-title":"Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo","volume":"70","author":"Sharma","year":"1996","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virol.2005.09.004_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/viro.2001.1212","article-title":"Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines","volume":"292","author":"Siler","year":"2002","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.virol.2005.09.004_bib62","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4049\/jimmunol.144.2.562","article-title":"IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2)","volume":"144","author":"Splawski","year":"1990","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.virol.2005.09.004_bib63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2004.10.018","article-title":"Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach","volume":"331","author":"Tan","year":"2005","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.virol.2005.09.004_bib64","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.4049\/jimmunol.170.5.2599","article-title":"Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias","volume":"170","author":"Woodberry","year":"2003","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.virol.2005.09.004_bib65","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/JVI.74.6.2628-2635.2000","article-title":"Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene","volume":"74","author":"zur Megede","year":"2000","journal-title":"J. Virol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682205005659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682205005659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:39:40Z","timestamp":1758584380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682205005659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0042682205005659"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2005.09.004","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced humoral HIV-1-specifc immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2005.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}